All In Biotech

Drug Trial Radar · NCT04868760

A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab(YERVOY)in Adult Healthy Chinese Male Volunteers

Compare IBI310 and Ipilimumab on the Pharmacokinetics, Safety, Tolerance and Immunogenicity of a Single Dose In Healthy Male Subjects: a Randomized Double-blind Parallel Controlled Phase I Clinical Study

Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

148

Actual

Start

May 31, 2021

Primary completion

May 2, 2022

Study completion May 2, 2022

Sponsor

Sponsor type
Industry
First posted
May 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trail will investigate the pharmacokinetics and safety of IBI310 and establish pharmacokinetics biosimilarity of IBI310 to ipilimumab (YERVOY)

Conditions

  • Healthy Subjects

Interventions

  • IpilimumabDrug

    Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.

  • IBI310Drug

    Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-time Curve (AUC0-inf)Time frame: From pre-dose to 1848hrs (78day)
  2. Maximum Plasma Concentration (Cmax)Time frame: From pre-dose to 1848hrs (78day)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.